NI-1701 is under clinical development by Light Chain Bioscience and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NI-1701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NI-1701 (TG-1801) is under development for the treatment of acute lymphocytic leukemia (ALL), B-cell non-Hodgkin lymphoma (NHL) including Richter's transformation, marginal zone B-cell lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), and unspecified B-cell lymphoma. It is administered through oral route. The drug candidate is a bi-specific monoclonal antibody, which acts by targeting CD47 and CD19. It is developed based on Kappa Lambda Body technology.
It was also under development for the treatment of diffuse large B-cell lymphoma and melanoma.
Light Chain Bioscience overview
Light Chain Bioscience formerly NovImmune is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company’s pipeline products include NI-0101, a toll-like receptor 4 monoclonal antibody for the treatment of chronic inflammation; NI-0401 a monoclonal antibody that targets CD3-epsilon, molecule that sits on the surface of a white blood cell; Emapalumab (NI-0501), a human anti-IFNy monoclonal antibody used for the treatment of hemophagocytic lymphohistiocytosis. It also develops NI-1201, an anti-IL6R monoclonal antibody to treat immune disorders; NI-1401, an Interleukin-17 monoclonal antibody used for the treatment of autoimmune and inflammatory diseases; NI-1701, an anti-CD19/anti-CD47 bispecific antibody that kills tumor cell; and NI-1801 an anti-CD47 that binds mesothelin-positive solid tumors. Light Chain Bioscience develops pipeline products using its proprietary bispecific antibody, and bispecific antibody platform. The company has partnership with Genentech, Tiziana Life Sciences, and Baxalta Inc for developing monoclonal and bispecific antibodies. Light Chain Bioscience is headquartered in Geneva, Switzerland.
For a complete picture of NI-1701’s drug-specific PTSR and LoA scores, buy the report here.